Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines

• Main Authors: Arianna Bonizzi (Author), Marta Truffi (Author), Marta Sevieri (Author), Raffaele Allevi (Author), Leopoldo Sitia (Author), Roberta Ottria (Author), Luca Sorrentino (Author), Cristina Sottani (Author), Sara Negri (Author), Elena Grignani (Author), Serena Mazzucchelli (Author), Fabio Corsi (Author)
• Format: Book
• Published: MDPI AG, 2019-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Everolimus (Eve) is an FDA approved drug that inhibits mammalian target of rapamycin (mTOR). It is employed in breast cancer treatment even if its responsiveness is controversial. In an attempt to increase Eve effectiveness, we have developed a novel Eve nanoformulation exploiting H-ferritin nanocag...